
    
      Subjects will undergo

        -  8-week baseline seizure period

        -  Randomization to ganaxolone or placebo

        -  Dose titrate for 2 weeks followed by 8 weeks of maintenance.

        -  Eligible subjects will be offered participation in the open-label extension study.

        -  Those not entering open-label will undergo a 6-week dose de-escalation to gradually
           taper ganaxolone.
    
  